-
Sector Analysis
Gene Therapy in Oncology
Unlike conventional treatments such as chemotherapy, gene therapy combines reduced treatment duration (one time treatment in some cases) with higher chances of cure in oncology. This novel therapeutic approach requires direct delivery of genetic material to the patient or in vitro genetic modification of patient cells and subsequent delivery to the patient, which is an uncharted territory in oncology and will necessitate the implementation of new regulatory guidelines and restructuring of the existing treatment algorithms in various oncology indications. In...
-
Sector Analysis
Colorectal Cancer: Competitive Landscape to 2026
Colorectal cancer (CRC) is a cancer that originates in either the colon or the rectum. CRC is the fourth leading cause of mortality among cancer patients in the world, and is the third most diagnosed cancer globally. Most cases of CRC present as adenocarcinomas, but other types of CRC include gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, leiomyosarcoma, melanoma, and squamous cell carcinoma. This report provides an assessment of the pipeline, clinical, and commercial landscape of CRC. Overall,...
-
Product Insights
Metastatic Colorectal Cancer Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Metastatic Colorectal Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Metastatic Colorectal Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Colorectal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
PharmaPoint: Colorectal Cancer – Global Drug Forecast and Market Analysis to 2025
The colorectal cancer (CRC) market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence, and the launch and uptake of premium-priced therapies. Traditionally, the CRC market has been dominated by two therapeutic classes: angiogenesis and EGFR inhibitors. However, the efficacy of these agents is limited by the insurgence of acquired resistance. Further, RAS...
-
Product Insights
Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Small-Cell Lung Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Small-Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) – Opportunity Analysis and Forecasts to 2024
Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of several targeted therapies, the field of SCLC has seen little advancement for several decades. For the purposes of this report,...